Cognitive functioning, cerebrospinal fluid Alzheimer's disease biomarkers and cerebral glucose metabolism in late‐onset epilepsy of unknown aetiology: A prospective study

• Published in: The European journal of neuroscience 2022-11, Vol.56 (9), p.5384-5396
• Main Authors: Fernandes, Mariana, Manfredi, Natalia, Aluisantonio, Lavinia, Franchini, Flaminia, Chiaravalloti, Agostino, Izzi, Francesca, Di Santo, Simona, Schillaci, Orazio, Mercuri, Nicola Biagio, Placidi, Fabio, Liguori, Claudio
• Format: Article
• Language: English
• Subjects: Aged; Alzheimer Disease - metabolism; Alzheimer's disease; Amyloid beta-Peptides - metabolism; anti‐seizure medication; Biomarkers; Biomarkers - metabolism; Cerebrospinal fluid; Cognition; Cognitive ability; Cognitive Dysfunction; Convulsions & seizures; Cortex (cingulate); Epilepsy; Etiology; Fluorodeoxyglucose F18; Glucose; Glucose metabolism; Humans; Neurodegenerative diseases; Peptide Fragments - cerebrospinal fluid; Positron emission tomography; Positron-Emission Tomography - methods; Prospective Studies; Seizures; Tau protein; tau proteins; tau Proteins - cerebrospinal fluid; β‐amyloid42
• ISSN: 0953-816X; 1460-9568
• DOI: 10.1111/ejn.15734

Epilepsy is increasing, being more common in older adults, with more than 20% of late‐onset cases with unknown aetiology (LOEU). Although epilepsy was associated with cognitive impairment, few studies evaluated the trajectories of cognitive decline in patients with LOEU. The present study aimed at assessing biomarkers of Alzheimer's disease (AD) in patients with LOEU and evaluating their cognitive performance for 12 months. For this study, 55 patients diagnosed with LOEU and 21 controls were included. Participants underwent cognitive evaluation and cerebrospinal fluid (CSF) biomarker analysis (ß‐amyloid42, tau proteins) before starting anti‐seizure medication and then repeated the cognitive evaluation at the 12‐month follow‐up. A subgroup of LOEU patients and controls also performed 18F‐fluoro‐2‐deoxy‐D‐glucose positron emission tomography (18F‐FDG PET) before starting anti‐seizure medication. At baseline, LOEU patients showed lower Mini‐Mental State Examination (MMSE) score, worse cognitive performance in several domains, lower β‐amyloid42 and higher tau proteins CSF levels than controls. Significantly reduced glucose consumption was observed in the right posterior cingulate cortex and left praecuneus areas in LOEU patients than controls, and this finding correlated with memory impairment. In the longitudinal analysis, a significant decrease in MMSE and an increase in verbal fluency scores were found in LOEU patients. These findings evidence that LOEU patients have a significant cognitive impairment, and alteration of cerebral glucose consumption and CSF AD biomarkers than controls. Moreover, they showed a progressive global cognitive decline at follow‐up, although verbal fluency was preserved. Further studies are needed to better understand the pathophysiological aspects of LOEU and its association with AD. Patients with LOEU showed a significant impairment of cognition, cerebral glucose consumption and CSF AD biomarkers compared with controls. Moreover, they showed a progressive global cognitive decline at follow‐up than controls.